John T, Grohe C, Goldman JW, Shepherd FA, et al. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial. J Thorac Oncol 2023 May 24:S1556-0864(23)00574.
PMID: 37236398